SCP
HAE icon

Syntal Capital Partners’s Haemonetics HAE Stock Holding History

Syntal Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,969
Closed -$2.29M – 114
2018
Q3 		$2.29M Buy
+19,969
New +$2.07M 0.8% 27

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Syntal Capital Partners's HAE Position: Q4 2018 in Review

Syntal Capital Partners sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 19,969 shares — an estimated $2.29M sold.

Syntal Capital Partners first reported a position in HAE in Q3 2018 and held it in 1 quarter. The position peaked at $2.29M in Q3 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Syntal Capital Partners reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Syntal Capital Partners sold 19,969 Haemonetics shares in Q4 2018, an estimated $2.29M.
  • Syntal Capital Partners first reported a position in Haemonetics in Q3 2018 and held it in 1 quarter.
  • Syntal Capital Partners's Haemonetics position peaked at $2.29M in Q3 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Syntal Capital Partners's 13F filing for Q4 2018, filed 13 Feb 2019.